Pharmaceutical

FDA accepts BeiGene’s sNDA for follicular lymphoma therapy

The US FDA has accepted for review BeiGene’s sNDA for Brukinsa plus obinutuzumab to treat follicular lymphoma.

Jul 13, 2023 - 20:00
FDA accepts BeiGene’s sNDA for follicular lymphoma therapy
The US FDA has accepted for review BeiGene’s sNDA for Brukinsa plus obinutuzumab to treat follicular lymphoma.
Read the original article

Tags:

Previous Article

Tenpoint raises funds to develop cell therapies for vision loss

Next Article

ICR to enter AI-powered cancer drug discovery partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: How are insurers handling the Alzheimer’s drug Leqembi and related scans?

STAT+: How are insurers handling the Alzheimer’s drug L...

Jul 12, 2023

FDA declines to approve Zealand Pharma’s hypoglycaemia therapy in infants

FDA declines to approve Zealand Pharma’s hypoglycaemia ...

Oct 10, 2024

Laurus Labs and IIT Kanpur partner for new gene therapy products

Laurus Labs and IIT Kanpur partner for new gene therapy...

Jun 19, 2023